/

Empresas

Ro

No verificado

Rona Therapeutics

Sobre qué escribimos

BiologíaCienciaFarmacéuticaFinanzasSanidad

5 Comunicados de prensa

Ver todos los comunicados de prensa

29/05/2025

Farmacéutica

Sanidad

Ciencia

Biología

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

Fuente

Rona Therapeutics

Editor

1.00

0

21/04/2025

Farmacéutica

Sanidad

Biología

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

Fuente

Rona Therapeutics

Editor

1.00

0

17/03/2025

Farmacéutica

Sanidad

Biología

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

Fuente

Rona Therapeutics

Editor

1.00

0

18/11/2024

Farmacéutica

Sanidad

Finanzas

Ciencia

Biología

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

Fuente

Rona Therapeutics

Editor

1.00

0

19/07/2024

Farmacéutica

Sanidad

Finanzas

Banca

Préstamos

Ahorro/Finanzas personales

Leasing

Gestión de bonos y obligaciones

Fondos de inversión

Eurobonos

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

Fuente

Rona Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0